Company intelligence / Profile preview
ApolloBio
Chinaapollobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ApolloBio's lead program, bizalimogene ralaplasmid (VGX-3100), is in Phase 3 development for squamous intraepithelial lesions of the cervix associated with HPV16/18, with promising efficacy and safety noted in earlier studies. Additional preclinical programs target COVID-19 (ABC-5100, a DNA vaccine) and various solid tumors (ABC-177).
- Therapeutic areas
- OncologyInfectious DiseasesWomen's Health
- Modalities
- DNA vaccineSmall moleculeAntibodyCAR-T cell therapyVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Inovio Pharmaceuticals
Beyond the preview
Go deeper on ApolloBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ApolloBio.